Last reviewed · How we verify
MW05
At a glance
| Generic name | MW05 |
|---|---|
| Also known as | MW05 injection |
| Sponsor | Mabwell (Shanghai) Bioscience Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MW05 CI brief — competitive landscape report
- MW05 updates RSS · CI watch RSS
- Mabwell (Shanghai) Bioscience Co., Ltd. portfolio CI